MTOR and neoplasm: In part to investigate potential targets for CAR T cell therapy in GBM, clinical trials are exploring a variety of immunotherapeutic strategies, one of which is the target IL13Ra2, a commonly expressed membrane‐bound protein in over 75% of GBMs that is associated with activating the mammalian target of rapamycin (mTOR) pathway favoring tumor growth [7].